VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of this approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.
The collaboration leverages VERAXA's proprietary click chemistry-powered conjugation technology, which the company notes demonstrates its potential application beyond its primary focus on solid tumors. The companies said they are discussing next steps in the collaboration, signaling continued progress in the development of targeted therapies for immune-mediated conditions.
This news is important because it validates the feasibility of using AOCs to enhance the efficacy of oligonucleotide therapeutics, which have shown promise in treating a range of diseases but often suffer from poor cellular uptake and off-target effects. The positive results suggest that VERAXA's conjugation platform could be broadly applicable, potentially expanding its pipeline and market opportunities.
For VERAXA, this collaboration could provide a strategic entry into the autoimmune and chronic immune disease space, diversifying its portfolio beyond oncology. The company's focus on antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, is complemented by this new application of its technology.
Secarna, a specialist in antisense oligonucleotide discovery and development, brings its expertise to the collaboration. The combined approach aims to improve the delivery and specificity of oligonucleotides, which are designed to modulate gene expression at the RNA level.
The companies highlighted that the early results support the potential of the AOC approach to selectively deliver therapeutic oligonucleotides to disease-specific cells. This selectivity is crucial for reducing side effects and improving treatment outcomes in chronic immune diseases, where prolonged therapy is often required.
As the collaboration progresses, further studies will be needed to confirm these findings in vivo and to evaluate the safety and efficacy of the AOC candidates. However, the initial success underscores the promise of combining advanced conjugation technologies with oligonucleotide therapeutics to create more effective treatments.
According to the press release, the full details are available at https://ibn.fm/IF9Cy. For more information about VERAXA Biotech, visit their newsroom at http://ibn.fm/VRXA.
